{"product_id":"dmac-vrio-analysis","title":"DiaMedica Therapeutics Inc. (DMAC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eCan DiaMedica Therapeutics Inc. (DMAC) secure a lasting competitive advantage? This VRIO analysis rigorously tests its core assets against the benchmarks of Value, Rarity, Inimitability, and Organization to reveal the true source of its market strength. Dive in now to see the distilled verdict on whether its current setup is built for sustainable dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: DM199 Drug Candidate Intellectual Property (IP) \u0026amp; Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core engine of DiaMedica Therapeutics Inc. (DMAC), the DM199 intellectual property. Honestly, for a clinical-stage company, this IP is everything; it’s the difference between a science project and a potential blockbuster. Here’s the breakdown on its competitive standing right now, based on their late 2025 figures.\u003c\/p\u003e\n\n\u003ch3 id=\"value\"\u003eValue: The Core Asset\u003c\/h3\u003e\n\u003cp\u003eDM199 is valuable because it’s the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein. This matters because it targets massive, unmet needs, most notably preeclampsia (PE). The recent interim results from the Preeclampsia Phase 2 trial showed promising dose-dependent blood pressure reductions and improved placental perfusion, which validates its therapeutic potential. That’s real value creation in action.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst recombinant KLK1 protein.\u003c\/li\u003e\n\u003cli\u003eTargets high unmet needs like preeclampsia.\u003c\/li\u003e\n\u003cli\u003ePositive proof-of-concept data supports value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity: A Unique Formulation in the US Market\u003c\/h3\u003e\n\u003cp\u003eWhat makes this rare isn't just the mechanism - the underlying KLK1 protein has been used outside the US for years - it’s the specific recombinant formulation and its application across three distinct indications: Preeclampsia (PE), Fetal Growth Restriction (FGR), and Acute Ischemic Stroke (AIS). For a company of DMAC's size, holding rights to a novel, synthetic version targeting these specific US\/EU indications is quite rare.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability: Patents vs. Mechanism\u003c\/h3\u003e\n\u003cp\u003eDirect imitation of the specific molecule and its parenteral delivery methods is tough because patents protect it. For instance, the U.S. formulation patent is set to expire in 2035, and a key composition of matter patent expires around 2033, not counting potential extensions. However, the underlying KLK1 mechanism itself is known science, so a competitor could theoretically pursue a different, non-infringing pathway to the same biological target. It’s a high barrier, but not an absolute wall.\u003c\/p\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization: Focused Investment and Runway\u003c\/h3\u003e\n\u003cp\u003eYes, DMAC is organized around this asset. They are putting serious capital behind it. Research and Development (R\u0026amp;D) expenses hit \u003cstrong\u003e$17.9 million\u003c\/strong\u003e for the nine months ending September 30, 2025, up from $12.6 million the prior year, showing focused investment in the global expansion of the ReMEDy2 trial and the PE study. Plus, the company has a clear operational runway; as of September 30, 2025, they held \u003cstrong\u003e$55.3 million\u003c\/strong\u003e in cash, which management projects will fund operations into the second half of 2027. That runway gives them time to execute.\u003c\/p\u003e\n\n\u003ch3 id=\"competitive-advantage\"\u003eCompetitive Advantage: Early Mover Status\u003c\/h3\u003e\n\u003cp\u003eRight now, the advantage is strong but definitely temporary. It’s an early-stage advantage driven by data exclusivity and the patent estate extending past the mid-2030s. Once key Phase 3 data reads out, or as the patent clock ticks down, that advantage shifts. The current strength is rooted in being the first mover with this specific recombinant drug in these indications.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the IP protection timeline:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Dimension\u003c\/td\u003e\n\u003ctd\u003eProtection Type\u003c\/td\u003e\n\u003ctd\u003eApproximate Expiration (No Extension)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulation (US)\u003c\/td\u003e\n\u003ctd\u003ePatent No. 9,616,015\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2035\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposition of Matter (EU)\u003c\/td\u003e\n\u003ctd\u003eEuropean Patent No. 2854841\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2033\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Standing\u003c\/td\u003e\n\u003ctd\u003eEarly-Stage Data Exclusivity\u003c\/td\u003e\n\u003ctd\u003eCurrent (Near-Term)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Preeclampsia\/Fetal Growth Restriction (PE\/FGR) Phase 2 Data\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positive interim data showing statistically significant blood pressure reduction and no placental transfer provides strong biological proof-of-concept.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eCohort 9 (Highest Dose, n=3)\u003c\/td\u003e\n\u003ctd\u003ePooled Cohorts 6–9 (n=12)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBP Reduction (5 min)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-35 mmHg\u003c\/strong\u003e (p\u0026lt;0.05)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-25mmHg\u003c\/strong\u003e (p=0.0003)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBP Reduction (5 min)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-15 mmHg\u003c\/strong\u003e (p\u0026lt;0.05)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-13mmHg\u003c\/strong\u003e (p=0.0007)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBP Reduction (24 hr)\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-20 mmHg\u003c\/strong\u003e (p=0.0031)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUterine Artery PI Reduction (2 hr)\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13.2%\u003c\/strong\u003e (p=0.0003)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e This positive, early-stage data in a space lacking approved treatments is rare and highly valuable for de-risking the asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNo approved pharmacological treatments for Preeclampsia (PE) in the United States and Europe.\u003c\/li\u003e\n\u003cli\u003eFetal Growth Restriction (FGR) affects an estimated \u003cstrong\u003e8–10%\u003c\/strong\u003e of pregnancies worldwide.\u003c\/li\u003e\n\u003cli\u003eIn the United States, approximately \u003cstrong\u003e120,000\u003c\/strong\u003e pregnancies are impacted annually by FGR.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific data set is unique to DiaMedica Therapeutics; competitors can’t replicate their trial results.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively enrolling the expansion cohort and planning the next US Phase 2 study, showing clear follow-through.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompleted Part 1a dose escalation cohort of the Phase 2 trial for preeclampsia.\u003c\/li\u003e\n\u003cli\u003eCurrently enrolling the expansion cohort (Part 1b).\u003c\/li\u003e\n\u003cli\u003eScreening for the Fetal Growth Restriction cohort (Part 3) expected to start soon.\u003c\/li\u003e\n\u003cli\u003eHeld in-person pre-IND meeting with the U.S. FDA to discuss plans for a U.S. Phase 2 DM199 study in preeclampsia.\u003c\/li\u003e\n\u003cli\u003eAs of Q3 2025, reported \u003cstrong\u003e$55 million\u003c\/strong\u003e in cash and investments, providing financial runway into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the nine months ended September 30, 2025, was \u003cstrong\u003e$21.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided the data holds up through Phase 3, as it establishes a strong clinical lead.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Safety\/Mechanism Data:\u003c\/strong\u003e DM199 demonstrated \u003cstrong\u003eno placental transfer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Acute Ischemic Stroke (AIS) ReMEDy2 Phase 2\/3 Trial\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is their most advanced trial, aiming for a major indication with established, albeit Asian-validated, therapeutic precedent.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA Phase 2\/3 trial nearing the interim analysis target of \u003cstrong\u003e200\u003c\/strong\u003e patients is a significant, rare milestone for a company with a market cap around \u003cstrong\u003e$313.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe trial design and patient pool are specific, but the slow enrollment (interim analysis targeted for \u003cstrong\u003eH2 2026\u003c\/strong\u003e) is a risk factor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is clearly structured to manage this global trial, supported by financial resources and personnel.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and investments as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$55.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFulltime Employees: \u003cstrong\u003e27\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as the advantage hinges on successful interim results and eventual approval, which is still a ways off.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Timeline\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Name\u003c\/td\u003e\n\u003ctd\u003eReMEDy2 (NCT# 05065216)\u003c\/td\u003e\n\u003ctd\u003eDM199 (rhKLK1) for AIS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Phase\/Design\u003c\/td\u003e\n\u003ctd\u003ePhase 2\/3, Adaptive Design, Randomized, Double-Blind, Placebo-Controlled\u003c\/td\u003e\n\u003ctd\u003eExcludes patients who received mechanical thrombectomy (MT) or are eligible for MT.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Analysis Target\u003c\/td\u003e\n\u003ctd\u003eNumber of subjects treated\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200\u003c\/strong\u003e participants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Enrollment Potential\u003c\/td\u003e\n\u003ctd\u003eFinal sample size determination\u003c\/td\u003e\n\u003ctd\u003eIntended to enroll approximately \u003cstrong\u003e300\u003c\/strong\u003e, may range up to \u003cstrong\u003e728\u003c\/strong\u003e patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim Results Timeline\u003c\/td\u003e\n\u003ctd\u003eExpected completion of analysis\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSecond half of 2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status\u003c\/td\u003e\n\u003ctd\u003eFDA Designation\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFast Track Designation\u003c\/strong\u003e granted in \u003cstrong\u003eSeptember 2021\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Financial Runway and Capital Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Having \u003cstrong\u003e$55.3 million\u003c\/strong\u003e in cash and short-term investments as of September 30, 2025, provides a runway into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e based on current plans.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A projected runway extending into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e for a pre-revenue company is notable, particularly following a recent capital infusion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e While cash itself is fungible, the organizational capability demonstrated by successfully executing a private placement in \u003cstrong\u003eJuly 2025\u003c\/strong\u003e to significantly bolster this position is an indicator of underlying strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The finance team secured capital through the \u003cstrong\u003eJuly 2025\u003c\/strong\u003e private placement, which is a key organizational strength that extended the operational runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e This advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e; the resource base is being continually depleted by the quarterly net loss, which was \u003cstrong\u003e$8.6 million\u003c\/strong\u003e for the third quarter ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial metrics relevant to the capital position as of the third quarter of 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (as of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on current plans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the three months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the nine months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJuly 2025 Private Placement Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBolstered cash from \u003cstrong\u003e$30.0 million\u003c\/strong\u003e on June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther detail on operational burn and capital deployment includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet cash used in operating activities for the nine months ended September 30, 2025, was \u003cstrong\u003e$21.3 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$15.6 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$6.4 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$5.0 million\u003c\/strong\u003e for the same period in the prior year.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$2.6 million\u003c\/strong\u003e, up from \u003cstrong\u003e$1.9 million\u003c\/strong\u003e for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eOverall net losses for the nine months ended September 30, 2025, totaled \u003cstrong\u003e$24.0 million\u003c\/strong\u003e, higher than the \u003cstrong\u003e$16.5 million\u003c\/strong\u003e reported for the same period in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: US FDA Regulatory Engagement\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Holding a productive in-person pre-IND meeting with the U.S. FDA for the US PE study is crucial for charting the path to US commercialization.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Direct, positive engagement with the FDA on a novel indication is a necessary, non-trivial step that many smaller biotechs struggle to initiate. The company reported holding this productive in-person pre-IND meeting with the U.S. FDA to discuss plans for the initiation of a U.S. Phase 2 DM199 Study in Preeclampsia, and is awaiting the meeting minutes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific guidance received is proprietary, but the process itself is standard, though navigating it is an acquired skill. The company is preparing to file an FDA Investigational New Drug (IND) application for a Phase 2B trial of DM199 for preeclampsia, with plans to start this trial in the US in 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The appointment of Dr. Julie Krop as Chief Medical Officer in August 2025 suggests a focus on strengthening regulatory and clinical leadership. Dr. Krop has over 20 years of experience as a strategic physician executive. In connection with her appointment, DiaMedica granted her an inducement stock option to purchase 450,000 shares of common stock.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a necessary hurdle, not a long-term differentiator once cleared. The company's financial position supports this regulatory advancement:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eRelevance to Regulatory Path\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eFunding for IND-enabling\/Phase 2 US Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003ctd\u003eSustaining regulatory engagement\/filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreeclampsia Phase 2 IST Trial Status\u003c\/td\u003e\n\u003ctd\u003ePart 1a Dose Escalation Cohort \u003cstrong\u003eComplete\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003ePrecursor to US IND submission\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAIS ReMEDy2 Phase 2\/3 Enrollment\u003c\/td\u003e\n\u003ctd\u003eNearing \u003cstrong\u003e50%\u003c\/strong\u003e of Target of \u003cstrong\u003e200\u003c\/strong\u003e Patients\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eOngoing clinical data generation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO Experience\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;20 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAppointment August 2025\u003c\/td\u003e\n\u003ctd\u003eLeadership for regulatory strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's recent financial performance metrics include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for the nine months ended September 30, 2025: \u003cstrong\u003e$24.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the nine months ended September 30, 2025: \u003cstrong\u003e$21.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q2 2025: \u003cstrong\u003e$7.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 EPS Loss: \u003cstrong\u003e$0.18\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe July 2025 private placement raised \u003cstrong\u003e$30.1 million\u003c\/strong\u003e, increasing the proforma cash balance to approximately \u003cstrong\u003e$60 million\u003c\/strong\u003e as of that time.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Established Asian Clinical Precedent (KLK1)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe KLK1 protein is an established therapeutic modality in Asia for stroke and vascular diseases, lending credibility to DM199’s mechanism.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAsian Precedent Data (KLK1)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Use (China)\u003c\/td\u003e\n\u003ctd\u003eSubacute treatment of Acute Ischemic Stroke (AIS) with Human Urinary KLK1 (HUK)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Treatments (2022)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;\u003cstrong\u003e600,000\u003c\/strong\u003e patients treated with HUK in China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Annual Sales (2016)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$150 million U.S.\u003c\/strong\u003e from two forms of KLK1 protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Evidence Base\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;\u003cstrong\u003e200\u003c\/strong\u003e clinical studies demonstrated efficacy with HUK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLeveraging established efficacy data from another region significantly reduces the perceived risk compared to a completely novel mechanism.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDM199 is the first recombinant form of human tissue kallikrein-1 (KLK1) developed by DiaMedica.\u003c\/li\u003e\n\u003cli\u003eBridging study established a dose of DM199 with a pharmacokinetic and pharmacodynamic profile comparable to the approved KLK1 product in Asia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe historical data exists, but translating that success into a US-approved recombinant product is a unique challenge DiaMedica Therapeutics is tackling.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe KLK1 protein, produced from porcine pancreas and human urine, has been used to treat patients in Japan, China and South Korea for decades.\u003c\/li\u003e\n\u003cli\u003eDM199 is being studied in the ReMEDy2 Trial, a Phase 2\/3 adaptive trial designed to enroll \u003cstrong\u003e350\u003c\/strong\u003e patients at \u003cstrong\u003e75\u003c\/strong\u003e sites in the United States for AIS.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is structured to build upon this foundation, focusing R\u0026amp;D on the US\/Western regulatory pathway.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and short-term investments were \u003cstrong\u003e$55 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway extends into the \u003cstrong\u003esecond half of 2027\u003c\/strong\u003e based on current plans.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the nine months ended September 30, 2025, totaled \u003cstrong\u003e$17.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAIS enrollment in the ReMEDy2 Phase 2\/3 Trial is nearing \u003cstrong\u003e50%\u003c\/strong\u003e of the target of \u003cstrong\u003e200\u003c\/strong\u003e patients for the interim analysis expected in \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, as long as the Asian data remains a valid reference point for regulators and investors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe US AIS market opportunity is estimated at over \u003cstrong\u003e$10 Billion\u003c\/strong\u003e, with over \u003cstrong\u003e80%\u003c\/strong\u003e of patients currently having no treatment option.\u003c\/li\u003e\n\u003cli\u003eIn the REDUX CKD study, a decrease in UACR of \u003cstrong\u003e-33%\u003c\/strong\u003e (P=0.002) was observed in the IgA Nephropathy cohort (n=11).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Focused Therapeutic Area Concentration\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFocused Therapeutic Area Concentration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: By focusing only on preeclampsia, FGR, and AIS - all ischemic diseases - the company concentrates its expertise and resources.\u003c\/p\u003e\n\u003cp\u003eRarity: Many biotechs spread themselves thin; this tight focus is relatively rare and efficient for a company of this size.\u003c\/p\u003e\n\u003cp\u003eImitability: Competitors can choose to focus, but DiaMedica Therapeutics has built its entire infrastructure around these specific indications.\u003c\/p\u003e\n\u003cp\u003eOrganization: The entire clinical and R\u0026amp;D strategy is aligned to these three areas, showing organizational coherence.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained, as long as the market need remains high and the company avoids mission creep.\u003c\/p\u003e\n\u003cp\u003eThe concentration on ischemic diseases is supported by significant, unaddressed patient populations and market opportunities:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eGlobal Annual Cases\u003c\/th\u003e\n\u003cth\u003eUS Annual Cases (Specific Subset)\u003c\/th\u003e\n\u003cth\u003eCurrent Treatment Status\u003c\/th\u003e\n\u003cth\u003eMarket Value (Select Data)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreeclampsia (PE)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;300 Thousand\u003c\/strong\u003e (PE\/FGR\/Hypertensive Disorders)\u003c\/td\u003e\n\u003ctd\u003eNo approved therapy\u003c\/td\u003e\n\u003ctd\u003eTop 7 Markets: \u003cstrong\u003eUSD 724.3 Million\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetal Growth Restriction (FGR)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~20 Thousand\u003c\/strong\u003e (Early-onset \u0026lt;32 weeks gestation)\u003c\/td\u003e\n\u003ctd\u003eNo currently approved treatment option\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute Ischemic Stroke (AIS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;7.5 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~700 Thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~80%\u003c\/strong\u003e of patients have no direct treatment options\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational alignment and commitment to this focus are evidenced by financial deployment and clinical progression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, Cash Equivalents and Investments as of September 30, 2025: \u003cstrong\u003e$55.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway into \u003cstrong\u003e2H 2027\u003c\/strong\u003e based on current plans.\u003c\/li\u003e\n\u003cli\u003eAIS ReMEDy2 Phase 2\/3 Trial interim analysis on the first \u003cstrong\u003e200\u003c\/strong\u003e patients expected in \u003cstrong\u003e2H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the nine months ended September 30, 2025: \u003cstrong\u003e$17.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eJuly 2025 private placement raised \u003cstrong\u003e$30.1 million\u003c\/strong\u003e at \u003cstrong\u003e$3.50\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe Preeclampsia Phase 2 IST Part 1a Dose Escalation Cohort is complete, with the Expansion Cohort now enrolling.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Experienced Clinical and Executive Team\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe team, including the CEO Rick Pauls and the recently appointed CMO Dr. Julie Krop, has the experience to navigate complex clinical trials and financing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Rick Pauls has served since 2009.\u003c\/li\u003e\n\u003cli\u003eCMO Dr. Julie Krop has more than 20 years of experience as a physician executive.\u003c\/li\u003e\n\u003cli\u003eDr. Krop was involved in the approval of three drugs at AMAG Pharmaceuticals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the small-cap space, securing top-tier medical leadership with specific therapeutic area experience is often rare.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eExecutive Role\u003c\/th\u003e\n\u003cth\u003eYears of Relevant Experience (Minimum Stated)\u003c\/th\u003e\n\u003cth\u003ePrior Company Experience Highlights\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresident \u0026amp; CEO (Rick Pauls)\u003c\/td\u003e\n\u003ctd\u003eSince 2009 tenure at DMAC; VC experience since 2002\u003c\/td\u003e\n\u003ctd\u003eCentreStone Ventures Managing Director; Structured Finance at General Motors Acceptation Corporation (1997–1999)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Medical Officer (Dr. Julie Krop)\u003c\/td\u003e\n\u003ctd\u003eMore than 20 years\u003c\/td\u003e\n\u003ctd\u003eCMO at PureTech Health; Drove IPO at Freeline Therapeutics; Three drug approvals at AMAG Pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Technology Officer (Dr. Ambarish Shah)\u003c\/td\u003e\n\u003ctd\u003eOver 25 years\u003c\/td\u003e\n\u003ctd\u003eVP at CSL Seqirus; Executive Director at Bristol-Myers Squib (Celgene)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Commercial Officer (Dominic Cundari)\u003c\/td\u003e\n\u003ctd\u003eOver 30 years\u003c\/td\u003e\n\u003ctd\u003eIndependent consultant for Genentech since 2009; Sales\/Marketing at Genentech (1988–2009)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKey personnel are hard to copy; their collective experience in drug development is a unique asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDr. Krop's specific experience in preeclampsia drug development is noted as beneficial.\u003c\/li\u003e\n\u003cli\u003eDirector Daniel J. O'Connor led Ambrx from a $40 million valuation to a $2 billion acquisition by Johnson \u0026amp; Johnson.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIncreased personnel costs in G\u0026amp;A suggest investment in expanding the team to support trial execution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGeneral and administrative (G\u0026amp;A) expenses were $8.2 million for the year ended December 31, 2023.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses were $7.6 million for the year ended December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses were $5.7 million for the nine months ended September 30, 2024, down from $6.0 million for the nine months ended September 30, 2023.\u003c\/li\u003e\n\u003cli\u003eThe 2023 increase in G\u0026amp;A was driven partly by increased personnel costs for team expansion.\u003c\/li\u003e\n\u003cli\u003eThe six months ended June 30, 2024 saw increased personnel costs for expanding the clinical team.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, as long as the key leaders remain in place and their institutional knowledge is retained.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Rick Pauls' total compensation in 2024 was $1,550,985.\u003c\/li\u003e\n\u003cli\u003eDr. Krop's appointment was effective August 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eDiaMedica Therapeutics Inc. (DMAC) - VRIO Analysis: Market Capitalization and Public Listing Status\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eBeing a publicly traded company on the \u003cstrong\u003eNasdaq Capital Market (DMAC)\u003c\/strong\u003e with a market capitalization of \u003cstrong\u003e$457.24 million\u003c\/strong\u003e as of December 5, 2025, allows access to public equity markets for financing, as evidenced by the definitive agreements for a \u003cstrong\u003e$30.1 million\u003c\/strong\u003e private placement completed in July 2025.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eMaintaining a public listing is a resource, though not unique, it provides a higher ceiling for capital raising than private-only firms. The ability to raise \u003cstrong\u003e$30.1 million\u003c\/strong\u003e in a single, non-agented private placement led by current investors demonstrates a current level of market access rarity.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can list, but the current valuation and investor base are unique to DiaMedica Therapeutics. The financing terms, such as the \u003cstrong\u003e$3.50\u003c\/strong\u003e per share purchase price in the July 2025 placement, reflect the specific market perception at that time.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company is organized to meet SEC reporting requirements, which is a necessary overhead for this resource. This organization supports the transparency required for public financing. The company reported \u003cstrong\u003e28\u003c\/strong\u003e employees as of December 30, 2024.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; the advantage is only present as long as the market values the equity at a level that makes raising capital accretive. The July 2025 placement increased the proforma cash balance to approximately \u003cstrong\u003e$60 million\u003c\/strong\u003e as of June 30, 2025, extending the cash runway into the second half of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe following table details key financial metrics related to the public status and recent financing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$457,239,914\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 5, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e52.08 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJuly 2025 Private Placement Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Issued in Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,606,426\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchase Price Per Share (Placement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProforma Cash Position\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$60 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto the second half of \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-July 2025 Placement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey financial data points supporting the organization and operational capacity derived from public status include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for the six months ended June 30, 2025, were \u003cstrong\u003e$11.5 million\u003c\/strong\u003e, up from \u003cstrong\u003e$7.6 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and short-term investments were \u003cstrong\u003e$30.0 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCash and short-term investments were \u003cstrong\u003e$55.3 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eNet losses for the three months ended June 30, 2025, were \u003cstrong\u003e$7.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company is targeting an interim analysis of the first \u003cstrong\u003e200\u003c\/strong\u003e patients in the stroke program in Q2 \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516151423125,"sku":"dmac-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/dmac-vrio-analysis.png?v=1740166644","url":"https:\/\/dcf-model.com\/products\/dmac-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}